BioSpace News Archive

AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis (i.e. a medical use patent) with its lead compound masitinib, based on findings from study AB06006 [1].

Brain Navi announced the completion of the 100th case utilizing its neurosurgical navigation robot NaoTrac.

Arthrex, a global leader in minimally invasive surgical technology and surgical skills education, has launched a new patient-focused resource, TheNanoExperience.com, highlighting the science and benefits of Nano arthroscopy, a modern, least-invasive orthopedic procedure that may allow for a quick return to activity and less pain.

Anbio Biotechnology (“Anbio”), a leading global diagnostic device and assay company, has announced its participation in Medlab Middle East, which will be held in Dubai from February 5 to 8, 2024.

Epiphany Dermatology announced it has expanded its presence in the Atlanta, Georgia, market through its partnership with Dr. Corinne Smith and her team at North Pointe Dermatology.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical resection.

The Bill & Melinda Gates Foundation announced its largest annual budget to date as it works toward the goal of a healthier, more prosperous world for all.

AnX Robotica is thrilled to announce FDA clearance for expanded indications of its NaviCam Small Bowel Video Capsule Endoscopy in both adults and children aged 2 years and above.

A new international biotech group was born from the integration of Hyris Ltd, an innovative biotech company renowned worldwide for its disruptive genetic testing platform, and Ulisse Biomed S.p.A., also known as UBM Group or “UBM” only, an Italian-based publicly traded biotech company appreciated for its innovative testing platforms.

NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the closing of the acquisition of the assets of SIBI Medical Inc., operating as the London Spine Institute in London, Ontario effective January 12, 2024.